Potentia Pharmaceuticals just announced a licensing deal worth "hundreds of millions of dollars" if its age-related macular degeneration (AMD) drug performs as hoped in Phase II clinical trials. The licensee,...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)